Compound Detail
CHEMBL1287853
FEDRATINIB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Basic Information
| ChEMBL ID | CHEMBL1287853 |
| Name | FEDRATINIB |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | JOOXLOJCABQBSG-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
300
Targets
492
Activities
4
Assay Types
12
PK Parameters
20
Publications
5
Known Names
8
Indications
2
Mechanisms
Molecular Properties
524.7
MW (Da)
4.82
ALogP
8
HBA
3
HBD
108.5
PSA (Ų)
0.35
QED
1
Ro5 Violations
10
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2019 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Tyrosine-protein kinase receptor FLT3 inhibitor | INHIBITOR | Receptor-type tyrosine-protein kinase FLT3 | ✓ | ✓ |
| Tyrosine-protein kinase JAK2 inhibitor | INHIBITOR | Tyrosine-protein kinase JAK2 | ✓ | ✓ |
Indications
Neoplasms Primary Myelofibrosis Primary Myelofibrosis Leukemia, Neutrophilic, Chronic Myelodysplastic Syndromes Myeloproliferative Disorders Kidney Diseases Liver Diseases
ATC Classification
L01EJ02
fedratinib
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Activity Summary
Kd 367 meas. best 8.96
IC50 121 meas. best 9.12
Ki 3 meas. best 6.98
EC50 1 meas. best 7.1
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Tyrosine-protein kinase JAK2 CHEMBL2971 | IC50 | 9.12 | 7.636 | 0.8 | 42 |
| Cyclin-G-associated kinase CHEMBL4355 | IC50 | 9.0 | 9.0 | 1.0 | 1 |
| Tyrosine-protein kinase JAK2 CHEMBL2971 | Kd | 8.96 | 8.665 | 1.1 | 2 |
| Cyclin-G-associated kinase CHEMBL4355 | Kd | 8.96 | 8.15 | 1.1 | 2 |
| Death-associated protein kinase 3 CHEMBL2468 | Kd | 8.92 | 8.92 | 1.2 | 1 |
| Receptor-type tyrosine-protein kinase FLT3 CHEMBL1974 | Kd | 8.31 | 7.6863 | 4.9 | 8 |
| Janus Kinase (JAK) CHEMBL2363062 | IC50 | 8.22 | 8.22 | 6.0 | 1 |
| Serine/threonine-protein kinase 16 CHEMBL3938 | Kd | 8.18 | 7.215 | 6.6 | 2 |
| Receptor-type tyrosine-protein kinase FLT3 CHEMBL1974 | IC50 | 7.98 | 6.7027 | 10.4 | 11 |
| Tyrosine-protein kinase JAK1 CHEMBL2835 | IC50 | 7.91 | 7.5629 | 12.3 | 7 |
| Serine/threonine-protein kinase DCLK3 CHEMBL6123 | Kd | 7.89 | 7.89 | 13.0 | 1 |
| Death-associated protein kinase 1 CHEMBL2558 | Kd | 7.8 | 7.8 | 16.0 | 1 |
| Proto-oncogene tyrosine-protein kinase receptor Ret CHEMBL2041 | IC50 | 7.77 | 6.505 | 17.0 | 10 |
| Tyrosine-protein kinase JAK1 CHEMBL2835 | Kd | 7.75 | 6.68 | 18.0 | 3 |
| Mitogen-activated protein kinase kinase kinase 19 CHEMBL6191 | Kd | 7.72 | 7.72 | 19.0 | 1 |
| Non-receptor tyrosine-protein kinase TYK2 CHEMBL3553 | Kd | 7.68 | 6.8967 | 21.0 | 3 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 7.62 | 7.62 | 24.0 | 2 |
| Death-associated protein kinase 2 CHEMBL3123 | Kd | 7.54 | 7.54 | 29.0 | 1 |
| AP2-associated protein kinase 1 CHEMBL3830 | IC50 | 7.5 | 7.5 | 32.0 | 1 |
| BMP-2-inducible protein kinase CHEMBL4522 | Kd | 7.5 | 6.895 | 32.0 | 2 |
| NUAK family SNF1-like kinase 1 CHEMBL5784 | Kd | 7.47 | 7.47 | 34.0 | 1 |
| AP2-associated protein kinase 1 CHEMBL3830 | Kd | 7.46 | 6.955 | 35.0 | 2 |
| Tyrosine-protein kinase Fyn CHEMBL1841 | Kd | 7.42 | 7.42 | 38.0 | 1 |
| Serine/threonine-protein kinase SIK1 CHEMBL6082 | Kd | 7.41 | 7.41 | 39.0 | 1 |
| Tyrosine-protein kinase ABL1 CHEMBL1862 | Kd | 7.4 | 6.9127 | 40.0 | 15 |
| Focal adhesion kinase 1 CHEMBL2695 | Kd | 7.38 | 7.07 | 42.0 | 2 |
| Platelet-derived growth factor receptor beta CHEMBL1913 | Kd | 7.35 | 7.35 | 45.0 | 1 |
| Serine/threonine-protein kinase 17B CHEMBL3980 | Kd | 7.35 | 7.35 | 45.0 | 1 |
| Mast/stem cell growth factor receptor Kit CHEMBL1936 | Kd | 7.34 | 6.6588 | 46.0 | 8 |
| NUAK family SNF1-like kinase 2 CHEMBL5698 | Kd | 7.31 | 7.31 | 49.0 | 1 |
| MV4-11 CHEMBL613835 | IC50 | 7.24 | 7.24 | 57.0 | 1 |
| Activated CDC42 kinase 1 CHEMBL4599 | Kd | 7.19 | 6.52 | 64.0 | 2 |
| Mitogen-activated protein kinase 7 CHEMBL5332 | Kd | 7.18 | 6.53 | 66.0 | 2 |
| Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha CHEMBL5969 | Kd | 7.18 | 7.18 | 66.0 | 1 |
| MOLM-13 CHEMBL3706572 | IC50 | 7.16 | 7.16 | 69.0 | 1 |
| Proto-oncogene tyrosine-protein kinase receptor Ret CHEMBL2041 | Kd | 7.15 | 6.748 | 71.0 | 5 |
| Tyrosine-protein kinase Lck CHEMBL258 | Kd | 7.14 | 7.14 | 72.0 | 1 |
| Tyrosine-protein kinase JAK3 CHEMBL2148 | Kd | 7.13 | 7.1 | 74.0 | 2 |
| Proto-oncogene tyrosine-protein kinase Src CHEMBL267 | Kd | 7.12 | 7.12 | 75.0 | 1 |
| NON-PROTEIN TARGET CHEMBL3879801 | EC50 | 7.1 | 7.1 | 79.0 | 1 |
| Serine/threonine-protein kinase ULK2 CHEMBL5435 | Kd | 7.1 | 7.1 | 79.0 | 1 |
| Tyrosine-protein kinase Fgr CHEMBL4454 | Kd | 7.09 | 7.09 | 82.0 | 1 |
| Serine/threonine-protein kinase TBK1 CHEMBL5408 | Kd | 7.04 | 6.345 | 92.0 | 2 |
| Serine/threonine-protein kinase RIO3 CHEMBL5659 | Kd | 7.04 | 7.0267 | 91.0 | 3 |
| Serine/threonine-protein kinase PLK4 CHEMBL3788 | Kd | 7.02 | 6.365 | 96.0 | 2 |
| Serine/threonine-protein kinase SIK2 CHEMBL5699 | Kd | 7.01 | 6.505 | 98.0 | 2 |
| Serine/threonine-protein kinase PknB CHEMBL1908385 | Kd | 7.0 | 7.0 | 100.0 | 1 |
| eIF-2-alpha kinase GCN2 CHEMBL5358 | Kd | 7.0 | 7.0 | 100.0 | 1 |
| SRSF protein kinase 2 CHEMBL5668 | Kd | 7.0 | 7.0 | 100.0 | 1 |
| Serine/threonine-protein kinase RIO1 CHEMBL5975 | Kd | 7.0 | 7.0 | 100.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 2825.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 14500.0 | ng.hr.mL-1 | Mus musculus |
| CL | 976.1 | mL.min-1.kg-1 | Mus musculus |
| CL | 3566.0 | mL.min-1.kg-1 | Mus musculus |
| Cmax | 8437.36 | nM | Mus musculus |
| Cmax | 18578.59 | nM | Mus musculus |
| Cmax | 1850.62 | nM | Homo sapiens |
| F | 102.0 | % | Mus musculus |
| T1/2 | 0.09333 | hr | Mus musculus |
| T1/2 | 5.45 | hr | Mus musculus |
| T1/2 | 2.88 | hr | Mus musculus |
| Tmax | 0.08 | hr | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 26254279 | 10.18632/oncotarget.4214 | Tyrosine-protein kinase JAK2 | 19 |
| 37796543 | 10.1021/acs.jmedchem.3c01242 | ADMET | 18 |
| 22037378 | 10.1038/nbt.1990 | Tyrosine-protein kinase ABL1 | 15 |
| 22037378 | 10.1038/nbt.1990 | Epidermal growth factor receptor | 12 |
| 22037378 | 10.1038/nbt.1990 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | 10 |
| 26254279 | 10.18632/oncotarget.4214 | Proto-oncogene tyrosine-protein kinase receptor Ret | 9 |
| 26254279 | 10.18632/oncotarget.4214 | Receptor-type tyrosine-protein kinase FLT3 | 9 |
| 22037378 | 10.1038/nbt.1990 | Mast/stem cell growth factor receptor Kit | 8 |
| 38843875 | 10.1021/acs.jmedchem.4c00197 | Unchecked | 7 |
| 22037378 | 10.1038/nbt.1990 | Receptor-type tyrosine-protein kinase FLT3 | 7 |
| 32911308 | 10.1016/j.ejmech.2020.112667 | Homo sapiens | 5 |
| 29191878 | 10.1126/science.aan4368 | Unchecked | 4 |
| 37796543 | 10.1021/acs.jmedchem.3c01242 | Tyrosine-protein kinase JAK1 | 4 |
| 33691794 | 10.1186/s13148-021-01037-1 | A549 | 4 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 4 |
| 37796543 | 10.1021/acs.jmedchem.3c01242 | Unchecked | 4 |
| 37796543 | 10.1021/acs.jmedchem.3c01242 | Bromodomain-containing protein 4 | 4 |
| 22037378 | 10.1038/nbt.1990 | Proto-oncogene tyrosine-protein kinase receptor Ret | 4 |
| 37796543 | 10.1021/acs.jmedchem.3c01242 | MDA-MB-231 | 3 |
| 19295546 | 10.1038/leu.2009.50 | Unchecked | 3 |
Data from ChEMBL 36 via Core Engine